Recent News

• 04.23.2025 - Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
• 04.11.2025 - DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.09.2025 - Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
• 04.09.2025 - 8-K - Current report
• 04.07.2025 - Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
• 04.01.2025 - DEF 14A - Definitive proxy statements
• 03.27.2025 - 8-K - Current report
• 03.27.2025 - Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
• 03.19.2025 - PRE 14A - Preliminary proxy statement not related to a contested matter or merger/acquisition
• 03.18.2025 - Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Recent Filings

• 04.11.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.09.2025 - 8-K Current report
• 04.09.2025 - EX-99.1 EX-99.1
• 04.01.2025 - DEF 14A Other definitive proxy statements
• 03.27.2025 - 8-K Current report
• 03.27.2025 - EX-99.1 EX-99.1
• 03.19.2025 - PRE 14A Other preliminary proxy statements
• 03.14.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]